Background: This study was conducted to determine the incidence and clinical characteristics of lacrimal drainage obstruction (LDO) in patients receiving S-1 chemotherapy. In multivariate analysis, total gastrectomy [versus partial gastrectomy: hazard ratio (HR), 2.9; P = 0.014] and creatinine clearance <50 ml/min (versus ≥50 ml/min: HR, 2.9; P = 0.038) were independent risk factors for the development of LDO.
. S-1 is widely used for patients with various solid tumors including gastric cancer (GC) [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . A Japanese phase III trial has shown that S-1 is an effective adjuvant therapy for GC patients who have undergone D2 dissection [1, 2] . S-1 has been also shown to be an effective drug for palliative chemotherapy in Eastern and Western GC patients with distant metastases [3] [4] [5] [6] [7] . Recently, European Medicines Agency has approved S-1 for palliative treatment of metastatic GC in combination with cisplatin.
Many studies have documented that systemic administration of antineoplastic agents can cause lacrimal drainage obstruction (LDO) and docetaxel is the most well-known drug causing LDO [11] [12] [13] [14] [15] [16] . Although there have been some reports on 5-FU-induced LDO, the incidence is known to be rare [17, 18] . Recently, some case and small-sized studies have been reported on LDO caused by S-1 [19] [20] [21] ; however, there have been no reports about S-1-induced LDO on a large scale. Therefore, we conducted this study to evaluate the incidence and clinical characteristics of S-1-induced LDO using a prospective cohort of GC patients receiving adjuvant S-1 chemotherapy. Considering the recent widespread use of S-1 as adjuvant therapy for locally advanced GC in Asian countries [1, 2] and the future prospect for the expanded use of S-1 in the treatment of various solid tumors including GC as palliative chemotherapy [3] [4] [5] [6] [7] [8] [9] [10] , large-scale studies on S-1-associated LDO, which has not been clearly recognized by clinicians, are definitely required.
materials and methods databases and patient population
This study was conducted using a GC patient cohort prospectively maintained at Seoul National University Bundang Hospital (SNUBH). The GC cohort was a subgroup of patient cohorts with various solid tumors, to which cancer patients were prospectively enrolled for a study titled 'pharmacogenetic/pharmacogenomic analyses on chemotherapeutic efficacy and toxicities in Korean cancer patients receiving chemotherapy' at SNUBH. In the database of the pharmacogenetic/pharmacogenomic study, clinical information on patient demographics, tumor characteristics, applied treatments, and toxic effects were included. However, as the database of the pharmacogenetic/pharmacogenomic study did not include sufficient data on ophthalmic adverse events during S-1 chemotherapy and the current study per se was not prospectively designed, insufficient data were retrospectively supplemented by electronic medical chart review [22, 23] .
Patients with gastric or gastroesophageal junction adenocarcinoma who underwent curative surgery (R0 resection) between November 2006 and April 2010 and received adjuvant S-1 chemotherapy were included. Patients were fully recovered from surgery and had adequate hepatic, renal, and bone marrow function before the initiation of adjuvant chemotherapy. Pathologic staging was carried out using the manual of the American Joint Committee on Cancer (sixth edition) and patients with stages II-IV (M0) were candidates for adjuvant chemotherapy; however, stage IB patients with additional risk factors (i.e. N2 lymph node metastasis by Japanese staging classification [24] ) also received S-1 when patients agreed to chemotherapy. This study was approved by the Institutional Review Board of SNUBH.
adjuvant S-1 therapy S-1 was administered orally for 4 weeks, followed by a 2-week rest period. S-1 was repeated every 6 weeks, and this interval was considered one cycle. S-1 was administered twice a day and the dose of S-1 was determined according to the body surface area (BSA), as follows: 40 mg for a BSA <1.25 m . The dose of S-1 was adjusted according to toxic effects, as previously reported [1, 25] . The duration of adjuvant S-1 chemotherapy was planned to be 1 year.
ophthalmologic evaluation
All the patients who were referred to the ophthalmology outpatient clinic underwent thorough examinations to evaluate the lacrimal drainage system. The patients underwent slit lamp biomicroscopic examinations to measure the heights of tear menisci and evaluate the patency of the puncta. A fluorescein dye disappearance test was carried out to identify physiologic tear drainage function. Lacrimal irrigation was carried out, and in the case of refluxed irrigation fluid through the opposite punctum, nasolacrimal duct obstruction or common canalicular obstruction was suspected and lacrimal probing was subsequently carried out to establish the diagnosis. If irrigation fluid was refluxed through the same punctum, canalicular obstruction was diagnosed. If irrigation fluid passed to the nasal cavity, but the fluorescein dye disappearance test showed delayed tear drainage function, partial nasolacrimal duct obstruction was diagnosed, and the patients were subject to dacryocystography to confirm stenosis of the nasolacrimal duct and to determine the level and severity of stenosis.
statistical analysis
The cumulative incidence of epiphora was calculated from the date of S-1 initiation until the first reported date of epiphora using the Kaplan-Meier method; patients who had died of cancer or other causes or who had been lost to follow-up without the development of epiphora were considered censored at the date of death or the last follow-up. Log-rank tests were carried out to determine differences in the cumulative incidence of LDO among comparison groups in univariate analyses. Cox proportional hazards models were carried out to analyze the influence of specified risk factors on the development of LDO in multivariate analysis. SPSS software was used for data analysis (SPSS, Inc., Chicago, IL) and P values <0.05 were considered significant; all tests were two-tailed.
results

patient characteristics
One hundred and seventy patients were included in this study. The median age was 58 years (range, 30-79 years), and 98 patients (58%) were male. The distribution of tumor stages was as follows: stage IB, 18 (11%); stage II, 89 (52%); stage IIIA, 42 (25%); stage IIIB, 15 (9%); and stage IV (M0), 6 (4%). Other clinical characteristics are presented in Table 1 . The median time to the initiation of S-1 chemotherapy from surgery was 29 days (range, 22-70 days). The median follow-up period of all incidence and clinical characteristics of epiphora and LDO
The median and mean numbers of S-1 chemotherapy cycles in enrolled patients were 9.0 (range, 1-9) and 7.3 [standard deviation (SD), ±2.7], respectively; 124 patients (73%) completed planned 1-year treatment of S-1. Thirty-one patients (18%) developed epiphora, which was not present before S-1 chemotherapy; the 1-year cumulative incidence of epiphora was 17% (Figure 1) . Among the 31 patients with epiphora who had been recommended to seek ophthalmologic evaluation, 25 patients underwent ophthalmic examinations and 6 patients declined further evaluation for epiphora. Among the 25 patients, 22 (88%) were diagnosed with LDO and 3 were diagnosed with dry eye syndrome. The median time to the onset of epiphora in the 22 patients with LDO was 2.9 months [95% confidence interval (CI), 1.6-4.0 months; range, 0.7-6. All 22 patients who were diagnosed with LDO were recommended to undergo surgical management. Four of the 22 patients underwent surgical procedures consisting of lacrimal silicone intubation with or without punctoplasties. Silicone tubes were left in place until S-1 therapy was completed, then removed after the completion of chemotherapy. Epiphora was resolved in all four patients who had undergone surgical procedures. However, among 18 patients who had not chosen to undergo surgical intervention, epiphora was not spontaneously improved and all patients had persistent symptoms until the time of the last visit.
risk factors for the development of LDO Additional analyses were carried out to determine risk factors for the development of LDO. Of 31 patients who had developed epiphora, 6 patients, who had not sought ophthalmologic evaluation and thus in whom the causes of epiphora were not verified, were excluded in the analyses. Therefore, the total number of patients included in the analyses was 164. All patients were divided into two groups ( patients with or without LDO after the initiation of chemotherapy). Three patients in whom the etiology of epiphora was identified as dry eye syndrome were classified into the group without LDO.
In univariate analyses using log-rank tests, age (≥65 versus <65 years), gender, performance status (Eastern Cooperative Oncology Group scales; 0 versus 1/2), the extent of gastrectomy [total gastrectomy (TG) versus partial gastrectomy (PG; subtotal or proximal gastrectomy)], and creatinine clearance (Ccr; ≥50 versus <50 ml/min) were included as independent parameters. Patients undergoing TG developed LDO more commonly than patients undergoing PG (P = 0.015; Figure 3A ). Patients with decreased Ccr (<50 ml/min) had a trend for developing LDO more frequently than those with Ccr ≥50 ml/min (P = 0.054; Figure 3B ). However, other clinical parameters were not associated with the development of LDO based on univariate analyses. In multivariate analysis using Cox proportional hazards model, both TG [hazard ratio (HR), 2.9; 95% CI, 1.2-6.7; P = 0.014] and Ccr <50 ml/min (HR, 2.9; 95% CI, 1.1-7.9; P = 0.038) were independent risk factors for the increased development of LDO (Table 2) . discussion Although S-1-induced LDO commonly develops and compromises quality of life of patients, as shown in this study, most clinicians have not recognized LDO as an important adverse event. This study was the first and largest report in the English literature describing the incidence and characteristics of S-1-induced LDO.
Esmaeli et al. [19] first reported three patients who developed epiphora after S-1 plus cisplatin chemotherapy. Park et al. [20] also reported two patients with epiphora after S-1 plus cisplatin chemotherapy. In the Japanese literature, Kitamura et al. [21] retrospectively reported 6 patients complaining of epiphora among 55 patients receiving S-1. In the present study, 31 of 170 patients (18%) developed epiphora after S-1 chemotherapy and 22 of 25 patients (88%) who underwent ophthalmologic examination were diagnosed with LDO. Symptoms of LDO (epiphora) commenced within Figure 1 . A Kaplan-Meier curve of the cumulative incidence of epiphora in patients receiving adjuvant S-1 chemotherapy (N = 170). One-year cumulative incidence of epiphora was 17%. Thirty-one patients (18%) developed epiphora and 25 of 31 patients underwent ophthalmologic examinations. Among these 25 patients, 22 (88%) were diagnosed with lacrimal drainage obstruction.
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7 months after the initiation of S-1. Although not all the 31 patients with epiphora underwent ophthalmologic examinations and were confirmed to have LDO, the incidence of LDO in GC patients receiving adjuvant S-1 chemotherapy is estimated to be ∼16% (18% × 0.88 = 16%). The median cumulative dose of S-1 at the onset of LDO was 4.3 g/m 2 and the median onset of LDO was 2.9 months after the initiation of S-1 therapy (mean onset, 3.4 months). Nasolacrimal duct was the most commonly involved site. In the report of Kitamura et al. [21] , the mean onset of epiphora was 5.7 months. With respect to the onset of epiphora, there is some possibility of delayed symptom reports by patients because they were contending with life-threatening GC, and thus epiphora might not be an important issue. This may explain some differences in the ranges of the onset time of epiphora among previous and our studies. For the same reason, it is also possible that the incidence of epiphora may be underestimated.
Currently known chemotherapeutic agents that can cause LDO are docetaxel [11] [12] [13] [14] [15] [16] , paclitaxel [26] , 5-FU [17, 18, 27] , and S-1 [19] [20] [21] ; LDO is most frequently associated with docetaxel [11] [12] [13] [14] [15] [16] . The incidence of epiphora in patients receiving docetaxel is reported from 10% to 77% [13] [14] [15] [16] ; proximal lacrimal drainage apparatuses such as punctum or canaliculus are mostly involved and LDO is not spontaneously Figure 2 . Anatomic sites of obstruction of the lacrimal drainage apparatus. After tears were secreted from lacrimal glands and distributed over eyes by eyelid blinking, tears enter the puncta at the medial ends of the eyelids, passing into the upper and lower canaliculi, the common canaliculus, the lacrimal sac, and through nasolacrimal duct into the nasal cavity: (A) The anatomic sites of the lacrimal drainage obstruction (LDO) were the punctum in 5 patients (23%), canaliculus in 3 patients (14%), and nasolacrimal duct in 19 patients (86%). Five patients had obstruction at two levels simultaneously; (B) photographs of lower punctum from a patient with normal open punctum (arrow) and (C) from a patient treated with S-1 showing punctal stenosis (arrow); (D) normal dacryocystographic finding showing patent contrast media passage through the lacrimal drainage system in a patient without LDO; (E) and (F) dacryocystographs of patients complaining of epiphora after the administration of S-1; (E) note the narrow right distal nasolacrimal duct and secondarily dilated proximal nasolacrimal duct and lacrimal sac (arrow), demonstrating partial nasolacrimal duct obstruction; (F) contrast media passed only through lower canaliculus, not reaching common canaliculus or lacrimal sac, demonstrating canalicular obstruction.
original articles Annals of Oncology reversible. LDO develops more frequently in patients receiving weekly docetaxel regimen than in patients receiving 3-weekly schedule [13, 14, 16] . However, there has been only one case report of paclitaxel-induced LDO [26] . 5-FU has been also reported as an LDO-inducing agent [17, 18, 27] . The incidence of LDO in patients receiving 5-FU is known to be ∼6% and most commonly involved sites are punctum and canaliculus [17, 18] . 5-FU is detected in tears of 5-FU-infused patients; however, the association between 5-FU concentration in tears and development of LDO was not clear and there have been contradictory reports without any well-designed studies [28, 29] . There has been no report on LDO caused by capecitabine.
In the present study, S-1 was shown to induce LDO more frequently than i.v. 5-FU. Interestingly, most of LDO cases [19/22 (86%) ] involved the nasolacrimal duct in GC patients receiving adjuvant S-1 therapy. There have been two suggested routes of systemically administered agents into the lacrimal drainage system. The first suggested mechanism involves direct secretion into the tear film [12] ; docetaxel and 5-FU are secreted into tears and passes along the lacrimal drainage, causing chronic inflammation and fibrosis of mucosa, resulting in LDO. The second suggested mechanism involves the damage of the lacrimal drainage system secondary to the systemic effects of chemotherapeutic agents [11] . If a drug is directly secreted into tears, proximal lacrimal drainage systems, such as the punctum or canaliculus, are more affected by the drug than distal systems, as in the cases of docetaxel or 5-FU. In contrast, if a drug exerts its effect on lacrimal drainage apparatus secondary to a systemic effect, the entire lacrimal drainage system would be evenly affected by the drug. The second mechanism may be one possible explanation of our results, where S-1-induced LDO occurred at entire lacrimal drainage apparatuses, ranging from the proximal to distal system. In addition, as CDHP, a component of S-1, is not contained in other fluoropyrimidines (5-FU or capecitabine), the high incidence of S-1-induced LDO might be related to the levels of CDHP in tears or blood rather than tegafur or 5-FU. Therefore, to clarify which hypothesis is appropriate, prospective studies evaluating the correlation between tear or blood concentrations of tegafur, 5-FU, or CDHP derived from S-1 and the development of LDO are needed.
There appears to be no linear dose-response relationship between cumulative S-1 dose and LDO because no new cases with LDO were identified >7 months after the initiation of S-1 in the current study. No relationship between the cumulative S-1 dose and LDO development suggests that other factors may affect the development of LDO. In our study, decreased renal function (Ccr <50 ml/min) and TG were independent risk factors for the development of LDO. It has been reported that patients with decreased renal function are less tolerant of S-1-based chemotherapy than patients with normal renal function [25, 30, 31] . As CDHP, a reversible inhibitor of DPD, is excreted mainly in the urine, lower CDHP clearance in patients with decreased renal function leads to a high-plasma CDHP concentration, which causes a sustained high-plasma 5-FU concentration. This may lead to more frequent adverse events in patients with a decreased Ccr than those with a preserved Ccr [25, 31] . In addition, most studies have shown that TG exerts more prominent effects on the pharmacokinetics of S-1 than subtotal gastrectomy [25, [32] [33] [34] . In the study of Kim et al. [32] , TG significantly increased the area under the curve of plasma 5-FU and CDHP. However, the impact of subtotal gastrectomy on pharmacokinetic profiles of S-1 was less prominent than TG [33, 34] . In the study of Iwasa et al. [25] , patients who underwent TG had a greater tendency to require dose reduction. However, as our analysis was retrospectively carried out, our suggestion about risk factors for developing LDO is hypothesis-generating and thus need to be confirmed in further prospective studies.
Epiphora caused by S-1-induced LDO responded well to the surgical management. In our study, only four patients agreed to surgical management perhaps because epiphora was not a relatively significant problem to patients compared with concerns about survival or experiencing other side-effects of S-1. However, intractable epiphora causes significant discomfort and deteriorates the quality of life. Therefore, early surgical intervention, such as lacrimal silicone intubation, should be actively considered to patients with LDO. Ideally, 
silicone tubes may be left in place until patients complete S-1 treatment or are no longer exposed to S-1. Lacrimal silicone intubation is a simple surgical procedure that can be done under local anesthesia and is quite effective for partial obstruction in the early stage of LDO. It is important for oncologists to be aware that LDO is treatable and the progression of LDO is preventable by early intervention. However, once complete closure occurs, complicated surgical procedures, such as dacryocystorhinostomy or conjunctivodacryocystorhinostomy with Pyrex glass tube insertion, are required to manage epiphora. Therefore, early diagnosis of LDO and timely surgical management with lacrimal silicone intubation are crucial to prevent complete closure and to avoid complicated surgical procedures.
Our study has some limitations. First, although this study was carried out using a prospective patient cohort, ophthalmologic data analyses were not preplanned and thus retrospectively done. Therefore, the incidence of epiphora and LDO may be underestimated and the analysis on risk factors for LDO development may be biased by unrecognized factors. However, our study definitely confirms that the development of LDO is not uncommon in patients receiving S-1. Second, as only 4 of 22 patients with LDO had undergone lacrimal silicone intubation, sufficient data on surgical outcomes could not be presented. However, considering persistent symptoms of already established LDO even after the completion of S-1 therapy in patients not undergoing surgical intervention and improved ophthalmic symptoms in all four patients after lacrimal silicone intubation suggest that early detection and intervention of LDO are very important.
In conclusion, given the high incidence of epiphora in S-1-treated patients and the fact that most of patients complaining of epiphora were diagnosed with LDO, oncologists should be alert to eye symptoms and cooperate with ophthalmologists in the early stages to improve the quality of life of patients and avoid more complicated ophthalmologic procedures. Univariate (log-rank tests) and multivariate analyses were carried out. In multivariate analysis, Cox proportional hazards models were used and proportionality assumptions were examined and met by the data. Variables with a P < 0.10 based on univariate analysis were included in the multivariate model and a forward stepwise method was used. Based on multivariate analysis, total gastrectomy and creatinine clearance <50 ml/min were independent risk factors for the increased development of LDO.
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